Related Experiment Video
Updated: May 28, 2026

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Published on: April 3, 2018
RAIDDing ER stress for oncolytic viral therapy
1Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. dmcconke@mdanderson.org
Abstract:
Oncolytic viruses exploit molecular differences between normal and cancer cells to selectively kill the latter. Results of a synthetic lethal screen described in this issue of Cancer Cell demonstrate that components of the unfolded protein response (UPR) limit virus-induced tumor cell killing and identify a strategy to utilize this knowledge.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Subviral Agents
Arboviral Encephalitis

